Quarterly report pursuant to Section 13 or 15(d)

NOTES PAYABLE (Details 1)

v3.21.2
NOTES PAYABLE (Details 1)
$ / shares in Units, $ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2020
USD ($)
Equity_Instrument
$ / shares
Dec. 31, 2019
USD ($)
Equity_Instrument
$ / shares
Debt Instrument [Line Items]    
Conversion Price | $ / shares $ 10.00  
Principal Outstanding $ 17,143 $ 17,142
Discount Amount 1,606 3,190
Carrying Amount $ 15,537 $ 13,952
Shares Underlying Notes | Equity_Instrument 4,638,333 1,444,291
2019 Convertible Debentures [Member]    
Debt Instrument [Line Items]    
Interest rate 10.00% 10.00%
Term of Notes 18 months 18 months
Principal Outstanding $ 9,200 $ 10,200
Discount Amount 1,606 3,185
Carrying Amount $ 7,594 $ 7,015
Shares Underlying Notes | Equity_Instrument 4,638,333 1,080,415
2019 Convertible Debentures [Member] | Minimum [Member]    
Debt Instrument [Line Items]    
Conversion Price | $ / shares [1] $ 2.00 $ 2.00
2019 Convertible Debentures [Member] | Maximum [Member]    
Debt Instrument [Line Items]    
Conversion Price | $ / shares [1] $ 9.52 $ 9.52
Convertible Debentures [Member]    
Debt Instrument [Line Items]    
Principal Outstanding $ 9,200 $ 10,200
Discount Amount 1,606 3,185
Carrying Amount $ 7,594 $ 7,015
Shares Underlying Notes | Equity_Instrument 4,638,333 1,080,415
Principal Outstanding, Current $ 9,200 $ 10,200
Discount Amount, Current 1,606 3,185
Convertible Debentures, Current $ 7,594 $ 7,015
Shares Underlying Notes, Current | Equity_Instrument 4,638,333 1,080,415
[1]

The notes are convertible to Emmaus Life Sciences, Inc. shares.